A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008) -

MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.0 个研究点目标入组 240 人开始时间: 2021年6月7日最近更新: 2021年8月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 240

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Has a histologically confirmed diagnosis of Stage IV CRC adenocarcinoma (as defined by AJCC version 8).
•2. Has locally confirmed dMMR/MSI-H.
•3. Has been previously treated for their disease and radiographically progressed per RECIST 1.1 on or after or could not tolerate standard treatment, which must include ALL of the following agents if approved and locally available in the country where the participant is randomized:
•a) Fluoropyrimidine, irinotecan and oxaliplatin.
•b) With or without an anti-VEGF monoclonal antibody (eg, bevacizumab)
•c) At least one of the anti-EGFR monoclonal antibodies (cetuximab or panitumumab) for RAS WT participants with left-sided tumors.
•4. Must not have had prior exposure to PD-1 or PD-L1 therapies as treatment for this disease.
•5. Has untreated Stage IV dMMR/MSI-H CRC with no prior chemotherapy or immunotherapy for this disease.
•6. Has radiographically progressed on-treatment with an anti-PD-1 mAb administered either as monotherapy or in combination with other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:
•a. Has received at least 2 doses of an approved anti-PD-1 mAb.
•b. Has shown disease progression after anti-PD-1 as defined by RECIST 1.1. The initial evidence of disease progression is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid symptom progression or clinical deterioration.
•c. Has documented progressive disease within 12 weeks from the last dose of anti-PD-1 mAb.
•- Progressive disease is determined according to RECIST 1.1
•- This determination is made by the investigator. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression
•7. Has had 0 to 1 prior systemic fluoropyrimidine based chemotherapy regimens
•8. Must not have been treated in Cohort A
•9. Is male or female and at least 18 years of age at the time of providing documented informed consent.
•10. Has a life expectancy of at least 3 months.
•11. Has ECOG Performance Status of 0 to 1 at screening and within 3 days before Cycle 1 Day 1.
•12. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
•Is not a WOCBP
•Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention.
•A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours for a urine test and 72 hours for a serum test before the first dose of study intervention.
•Refer to protocol for the rest of inclusion criteria
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 120
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 120

排除标准

•1. Has received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137, PD-L1).
•2. Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention.
•3. If the participant had a surgery and they have not recovered adequately from the procedure and/or any complications from the surgery before starting study intervention.
•4. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<=2 weeks of radiotherapy) to non-CNS disease.
•5. Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
•6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
•7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
•8. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years.
•9. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression) for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days before the first dose of study intervention.
•10. Has severe hypersensitivity (>=Grade 3) to pembrolizumab, quavonlimab and/or any of their excipients.
•11. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
•Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
•Exception: Participants with a history of inflammatory bowel disease (eg, Crohn’s disease or ulcerative colitis) may not participate, regardless of treatment history.
•12. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
•13. Has an active infection requiring systemic therapy (eg, tuberculosis, known viral or bacterial infections, etc.).
•14. Has a known history of HIV infection.
•15. Has known active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) or active Hepatitis C virus (defined as HCV RNA [qualitative] is detected or anti-HCV Ab positive) infection.
•16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
•Refer to protocol for the rest of exclusion criteria

研究者

发起方

MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.

相似试验

进行中（未招募）

1 期

A Multi Arm Study in Participants with MSI-High Metastatic Colorectal CancerMicrosatellite Instability-High (MSI-H) or Mismatch Repair Deficient(dMMR) Stage IV Colorectal CancerMedDRA version: 21.0Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10079619Term: MSI-highSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-005114-18-LTMerck Sharp & Dohme LLC320

进行中（未招募）

1 期

EUCTR2020-005114-18-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.240

进行中（未招募）

1 期

A Multi Arm Study in Participants with MSI-High Metastatic Colorectal CancerParticipants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal CancerMedDRA version: 20.1Level: LLTClassification code: 10079619Term: MSI-high Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10010035Term: Colorectal cancer stage IV Class: 100000004864

CTIS2022-502100-70-00Merck Sharp & Dohme LLC387

进行中（未招募）

1 期

EUCTR2020-005114-18-GRMerck Sharp & Dohme LLC320

进行中（未招募）

1 期

EUCTR2020-005114-18-HUMerck Sharp & Dohme LLC320